BBIO vs. KYMR: BridgeBio Pharma vs. Kymera Therapeutics Stock Comparison
How do BridgeBio Pharma (BBIO) and Kymera Therapeutics (KYMR) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
BridgeBio Pharma (BBIO) and Kymera Therapeutics (KYMR) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | BBIO | KYMR |
|---|---|---|
| Name | BridgeBio Pharma Inc. | Kymera Therapeutics Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 14.47 billion USD | 11.25 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | June 27, 2019 | August 21, 2020 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | BBIO | KYMR |
|---|---|---|
| Total Return (1Y) | 22.70% | 131.52% |
| Total Return (3Y, Annualized) | 40.97% | 111.65% |
| Total Return (5Y, Annualized) | 8.25% | 15.68% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | BBIO | KYMR |
|---|---|---|
| Volatility (1Y, Annualized) | 44.39% | 62.83% |
| Beta (5Y) | 0.93 | 2.00 |
| Max Drawdown (5Y) | -89.79% | -83.27% |
| Avg. Volume (3M) | 2.68M | 833.05K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | BBIO | KYMR |
|---|---|---|
| Sharpe Ratio (1Y) | 0.41 | 2.03 |
| Sortino Ratio (1Y) | 0.63 | 4.16 |
Profitability
ROE (TTM)
BridgeBio Pharma (BBIO) has no ROE value reported for this period; Kymera Therapeutics (KYMR) reports a negative figure of -27.29%, which needs context because negative ROE can reflect losses or negative shareholders’ equity.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- BBIO
- --
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
-27.29%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- KYMR
- -27.29%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
BridgeBio Pharma (BBIO) reports a negative net margin of -59.84%, usually indicating a net loss over the period. Meanwhile Kymera Therapeutics (KYMR) reports 0.00%, ranking against industry peers normally.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
-59.84%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
- BBIO
- -59.84%
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 18.05%
- Q3
- 4.78%
- KYMR
- 0.00%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both BridgeBio Pharma (BBIO) at -3.30% and Kymera Therapeutics (KYMR) at -396.04% report negative operating margin values, usually indicating operating losses over the period.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
-3.30%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- BBIO
- -3.30%
- Q1
- -78.82%
- Min
- -207.40%
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
-396.04%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
- KYMR
- -396.04%
Profitability Metrics
| Metric | BBIO | KYMR |
|---|---|---|
| ROE (TTM) | -- | -27.29% |
| ROA (TTM) | -13.97% | -17.64% |
| Net Margin (TTM) | -59.84% | 0.00% |
| Operating Margin (TTM) | -3.30% | -396.04% |
| Gross Margin (TTM) | 94.34% | 0.00% |
Growth
Revenue Growth
BridgeBio Pharma (BBIO) at 126.26% sits in the top revenue growth quartile, while Kymera Therapeutics (KYMR) at -16.70% is in the bottom quartile, showing a clear gap in revenue momentum.
EPS Growth
Neither BridgeBio Pharma (BBIO) nor Kymera Therapeutics (KYMR) reports a EPS growth value for this period, so a direct comparison isn't possible.
Growth Metrics
| Metric | BBIO | KYMR |
|---|---|---|
| Revenue Growth (YoY) | 126.26% | -16.70% |
| Revenue Growth (3Y CAGR) | 86.30% | -5.74% |
| EPS Growth (YoY) | -- | -- |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Kymera Therapeutics (KYMR) at 11.13 keeps current ratio within its industry’s typical mid-range, while BridgeBio Pharma (BBIO) at 2.09 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for BBIO.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.09
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- BBIO
- 2.09
- Min
- 0.10
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
11.13
- Max
- 25.13
- Q3
- 12.13
- KYMR
- 11.13
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Only one side’s leverage can be read here: Kymera Therapeutics (KYMR) carries debt-to-equity ratio of 0.05 against its industry range, while BridgeBio Pharma (BBIO) reports no figure this period.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
- BBIO
- --
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.05
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- KYMR
- 0.05
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | BBIO | KYMR |
|---|---|---|
| Current Ratio (MRQ) | 2.09 | 11.13 |
| Debt / Equity (MRQ) | -- | 0.05 |
| Net Debt / EBITDA | -- | -- |
Dividends
Dividend Yield (TTM)
Neither BridgeBio Pharma (BBIO) nor Kymera Therapeutics (KYMR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BBIO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- KYMR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither BridgeBio Pharma (BBIO) nor Kymera Therapeutics (KYMR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BBIO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- KYMR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | BBIO | KYMR |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Neither BridgeBio Pharma (BBIO) nor Kymera Therapeutics (KYMR) reports a P/E ratio value for this period, so a direct comparison isn’t possible.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- BBIO
- --
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- KYMR
- --
P/S Ratio (TTM)
BridgeBio Pharma (BBIO) at 15.31 prices around its industry’s typical P/S ratio, while Kymera Therapeutics (KYMR) at 110.00 clears its benchmark range — KYMR looks notably rich on sales.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
15.31
- Max
- 58.18
- Q3
- 25.77
- BBIO
- 15.31
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
110.00
- KYMR
- 110.00
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
BridgeBio Pharma (BBIO) reports a negative P/B ratio of -5.59, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Kymera Therapeutics (KYMR) reports 6.96, ranking against industry peers normally.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
-5.59
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- BBIO
- -5.59
- Min
- -5.59
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.96
- Max
- 13.53
- KYMR
- 6.96
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | BBIO | KYMR |
|---|---|---|
| P/E Ratio (TTM) | -- | -- |
| P/S Ratio (TTM) | 15.31 | 110.00 |
| P/B Ratio (MRQ) | -5.59 | 6.96 |
| Free Cash Flow Yield (TTM) | -1.98% | -1.46% |